Personalis (NASDAQ:PSNL) CFO Sells $675,488.18 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aaron Tachibana also recently made the following trade(s):

• On Thursday, June 4th, Aaron Tachibana sold 40,000 shares of Personalis stock. The shares were sold at an average price of $12.01, for a total transaction of $480,400.00.
• On Friday, May 29th, Aaron Tachibana sold 38,799 shares of Personalis stock. The stock was sold at an average price of $11.58, for a total transaction of $449,292.42.

Personalis Stock Performance

Shares of Personalis stock opened at $13.02 on Monday. The firm has a fifty day moving average of $8.42 and a two-hundred day moving average of $8.28. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -12.76 and a beta of 2.27. Personalis, Inc. has a 52 week low of $3.84 and a 52 week high of $13.37.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. As a group, research analysts forecast that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PSNL. Aberdeen Group plc raised its position in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares during the period. Oracle Investment Management Inc. bought a new position in shares of Personalis during the 3rd quarter valued at about $1,496,000. ARK Investment Management LLC grew its position in shares of Personalis by 11.3% in the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after purchasing an additional 802,268 shares during the period. Howland Capital Management LLC grew its position in shares of Personalis by 65.5% in the 4th quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock valued at $4,355,000 after purchasing an additional 216,442 shares during the period. Finally, Next Century Growth Investors LLC bought a new stake in Personalis during the 4th quarter worth approximately $4,970,000. 61.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on PSNL. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. BTIG Research lowered their price target on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Morgan Stanley cut their price target on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Personalis presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.